Treatment with cyclosporine results in improvements, albeit statistically nonsignificant, in the Severity of Alopecia Tool score and eyelash and eyebrow assessment scales among patients with moderate-to-severe alopecia areata (AA), a recent study has shown.
Transcutaneous vagal nerve stimulation (tVNS) delivered through a device attached to the ear can help rebalance the autonomic nervous system of individuals aged ≥55 years, and thus promote healthy ageing, a new study suggests.
Roxadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is noninferior to parenteral epoetin alfa and performs better than placebo for correcting anaemia in kidney disease patients who are or not undergoing dialysis, according to the results of two phase III trials from China.
The addition of abobotulinumtoxinA (aboBTX-A) – one of three commercial preparations of botulinum toxin (BTX) type A – to phosphodiesterase type 5 inhibitors (PDE5-Is) or prostaglandin E1 (PGE1) led to favourable outcomes in men with erectile dysfunction (ED), a new study shows.
Use of the proton pump inhibitor (PPI) pantoprazole does not cut the risk of upper gastrointestinal events but may reduce the risk of bleeding from gastroduodenal lesions in patients on low-dose anticoagulants and/or antiplatelet therapy, a study has shown.
Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.
Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau,
07 Aug 2019
Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.
Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1cof 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.